1055331-73-1

Basic information

• Product Name: Benzoic acid, 2-broMo-5-fluoro-3-nitro-
• Synonyms: Benzoic acid, 2-broMo-5-fluoro-3-nitro-;2-BroMo-5-fluoro-3-nitrobenzoic acid
• CAS NO: 1055331-73-1
• Molecular Formula: C₇H₃BrFNO₄
• Molecular Weight: 264.0054232
• Mol File: 1055331-73-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 333.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.967±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.51±0.20(Predicted)
• CAS DataBase Reference: Benzoic acid, 2-broMo-5-fluoro-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-broMo-5-fluoro-3-nitro-(1055331-73-1)
• EPA Substance Registry System: Benzoic acid, 2-broMo-5-fluoro-3-nitro-(1055331-73-1)

Safety Data

• Hazardous Substances Data: 1055331-73-1(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 2-bromo-5-fluoro-3-nitro- is a chemical compound that contains a benzene ring with a carboxylic acid functional group, as well as a bromine, fluorine, and nitro substituent. It is used in the synthesis of various pharmaceuticals and agrochemicals, as well as in the production of dyes and perfumes. Benzoic acid, 2-broMo-5-fluoro-3-nitro- is also used as a reagent in organic chemistry reactions, and has been studied for its potential antibacterial and antifungal properties. Its unique combination of functional groups makes it a versatile compound with a wide range of potential applications in both the laboratory and industrial settings. However, it is important to handle this compound with caution, as it can be harmful if ingested or inhaled, and may cause irritation to the skin and eyes.

Upstream product

• 394-28-5 2-Bromo-5-fluorobenzoic acid 
• 328547-12-2 methyl 2-bromo-5-fluoro-3-nitrobenzoate 

Downstream Products

• 328547-12-2 methyl 2-bromo-5-fluoro-3-nitrobenzoate 
• 1342063-52-8 methyl 3-amino-2-bromo-5-fluorobenzoate 
• 884497-46-5 methyl 3-amino-5-fluorobenzoate 

Relevant articles and documents

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R1a, R2a, R1b, R2b, R1c, R2c, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.